Core Points - Pharming Group N.V. will hold its 2025 Annual General Meeting of Shareholders on June 11, 2025, at 14:00 CEST [1] - Dr. Elaine Sullivan is nominated for appointment as a new Non-Executive Director for a four-year term [2] - The AGM agenda includes reappointments of existing Non-Executive Directors, the proposal to reappoint Deloitte Accountants B.V. as the external auditor for 2025, and the renewal of share issuance and repurchase authorizations [3] Company Profile - Pharming Group N.V. is a global biopharmaceutical company focused on developing innovative medicines for patients with rare and life-threatening diseases [9] - The company is headquartered in Leiden, the Netherlands, and operates in over 30 markets worldwide [9] - Pharming's portfolio includes both small molecules and biologics [9] Director Profile - Dr. Elaine Sullivan has extensive experience in the pharmaceutical and biotech industry, with a successful track record in drug development and business [5] - She has served as a Non-Executive Director at Zealand Pharma A/S and hVIVO, and has held leadership roles at Eli Lilly and AstraZeneca [6][7] - Dr. Sullivan holds a PhD in Molecular Virology and a BSc in Molecular Biology [8]

Core Points - Pharming Group N.V. announced the adoption of all proposals at the Extraordinary General Meeting of Shareholders, including the appointment of Mr. Fabrice Chouraqui as Executive Director and CEO for a four-year term [1][2] - Mr. Chouraqui succeeds Mr. Sijmen de Vries, who will remain as a strategic advisor until December 31, 2025, to ensure a smooth transition [2] - The remuneration package for Mr. Chouraqui was also approved by shareholders [2] Company Overview - Pharming Group N.V. is a global biopharmaceutical company focused on transforming the lives of patients with rare and life-threatening diseases [5] - The company is engaged in the commercialization and development of protein replacement therapies and precision medicines, including small molecules and biologics [5] - Pharming is headquartered in Leiden, the Netherlands, and operates in over 30 markets across North America, Europe, the Middle East, Africa, and Asia-Pacific [5] Leadership Commentary - Dr. Richard Peters, Chairman of the Board, expressed a warm welcome to Mr. Chouraqui and acknowledged the significant contributions of the outgoing CEO, Mr. de Vries, over the past 16 years [4]